Iovance Biotherapeutics (IOVA)
(Delayed Data from NSDQ)
$2.58 USD
-0.17 (-6.18%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $2.60 +0.02 (0.78%) 4:52 PM ET
5-Strong Sell of 5 5
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
IOVA 2.58 -0.17(-6.18%)
Will IOVA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IOVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IOVA
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut
IOVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates
IOVA Q4 Earnings Beat, Stock Down on Looming Economic Uncertainty
Other News for IOVA
Iovance Biotherapeutics Is Waking Up - Price Action Screams Breakout, But Fundamentals Demand Patience
12 Health Care Stocks Moving In Thursday's Intraday Session
Iovance Biotherapeutics Inc (IOVA) Announces Upcoming Financial Results and Corporate Updates | ...
12 Health Care Stocks Moving In Wednesday's Intraday Session
Unusually active option classes on open July 23rd